Overview

Open-label Study to Assess the Safety and Efficacy of TRP-8802 With Psychotherapy in Adult Participants With Fibromyalgia

Status:
Not yet recruiting

Trial end date:
2024-05-01

Target enrollment:

Participant gender:

Summary

The pressing need for effective fibromyalgia (FM) treatments, the known safety of psilocybin therapy, and the mechanistic plausibility for potential benefit provide a backdrop for investigating TRP-8802 therapy as a treatment for FM. The primary objective of this study is to evaluate the clinical benefit of oral TRP-8802 in concert with psychotherapy to treat chronic pain symptoms in patients with FM.

Phase:

Phase 2

Details

Lead Sponsor:

TRYP Therapeutics

Treatments:

Psilocybin